2007
DOI: 10.1007/s00280-007-0566-9
|View full text |Cite
|
Sign up to set email alerts
|

Preclinical studies of treosulfan demonstrate potent activity in Ewing’s sarcoma

Abstract: Our results suggest that treosulfan has efficacy against Ewing's sarcoma cells in vitro and in mice. Therefore, controlled trials examining the role of treosulfan in patients with Ewing's sarcoma are warranted.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
19
0

Year Published

2008
2008
2015
2015

Publication Types

Select...
6
3

Relationship

3
6

Authors

Journals

citations
Cited by 25 publications
(20 citation statements)
references
References 37 publications
1
19
0
Order By: Relevance
“…Consistent with in vivo results (14), rapamycin exposures to the PuMA significantly inhibited metastatic progression at 1 μM. The anticancer activity of treosulfan, a nontargeted cytotoxic chemotherapy, has been shown in vitro and in vivo against a variety of pediatric sarcoma cell lines (15). Significant activity of these agents was confirmed in the PuMA following its addition early or late during the course of metastatic progression.…”
Section: Figuresupporting
confidence: 69%
“…Consistent with in vivo results (14), rapamycin exposures to the PuMA significantly inhibited metastatic progression at 1 μM. The anticancer activity of treosulfan, a nontargeted cytotoxic chemotherapy, has been shown in vitro and in vivo against a variety of pediatric sarcoma cell lines (15). Significant activity of these agents was confirmed in the PuMA following its addition early or late during the course of metastatic progression.…”
Section: Figuresupporting
confidence: 69%
“…1,2 Treosulfan has a broad spectrum of antitumour activity and it is registered for the treatment of ovarian carcinoma. [3][4][5][6] In addition, it was demonstrated both in vivo and in vitro that treosulfan reveals an excellent toxicity against all stem cell lines of the BM and this caused that it was recently administered in high doses within the conditioning regimen prior to allogeneic haematopoietic SCT in patients with haematological malignancies. 7 Despite the clinical use of the oral and i.v.…”
Section: Introductionmentioning
confidence: 99%
“…Treosulfan (L-threitol-1, 4-bis-methanesulfonate) is a water-soluble bifunctional alkylating agent and has been recently shown to be active against ES in vitro and in an orthotopic mouse xenograft-model. 18 …”
mentioning
confidence: 97%